1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cholera - Pipeline Review, H1 2016

Cholera - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 57 pages

Cholera - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cholera - Pipeline Review, H1 2016’, provides an overview of the Cholera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cholera
- The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects
- The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cholera

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cholera
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cholera - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cholera Overview 7
Therapeutics Development 8
Pipeline Products for Cholera - Overview 8
Pipeline Products for Cholera - Comparative Analysis 9
Cholera - Therapeutics under Development by Companies 10
Cholera - Therapeutics under Investigation by Universities/Institutes 11
Cholera - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Cholera - Products under Development by Companies 15
Cholera - Products under Investigation by Universities/Institutes 16
Cholera - Companies Involved in Therapeutics Development 17
Akthelia Pharmaceuticals Limited 17
Beijing Minhai Biotechnology Co., Ltd 18
PaxVax, Inc. 19
Cholera - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AKT-10082 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
cholera (trivalent) vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
crofelemer DR - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
gram-negative bacterial infections vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
IMSUTMR-1501 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
PXVX-0200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules for Bacterial Infections - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Synthetic Peptides to Disrupt Cell Wall for Bacterial and Fungal Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Cholera - Recent Pipeline Updates 42
Cholera - Dormant Projects 46
Cholera - Discontinued Products 47
Cholera - Product Development Milestones 48
Featured News and Press Releases 48
Dec 16, 2015: U.S. Food and Drug Administration Accepts Biologics License Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora 48
Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix 48
Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial 49
Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum 50
Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 50
May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 51
Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 52
Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 53
Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 54
Mar 19, 2012: FDA Accepts PaxVax's IND for Single-Dose Oral Cholera Vaccine 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Cholera, H1 2016 8
Number of Products under Development for Cholera - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Cholera - Pipeline by Akthelia Pharmaceuticals Limited, H1 2016 17
Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 18
Cholera - Pipeline by PaxVax, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Cholera Therapeutics - Recent Pipeline Updates, H1 2016 42
Cholera - Dormant Projects, H1 2016 46
Cholera - Discontinued Products, H1 2016 47

List of Figures
Number of Products under Development for Cholera, H1 2016 8
Number of Products under Development for Cholera - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, ...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin ...

Rabies - Pipeline Review, H2 2016

October 2016 $ 2000

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.